Influence of pirarubicin intravesical therapy on serum sICAM-1, VEGF and MMP-9 in patients with superficial bladder cancer

Lin Chen; Liu Xiange; Xiang Jun; Qiao Liang; Zhao Mingqi

doi:10.19558/j.cnki.10-1020/r.2018.05.014

Abstract：Objective:To explore the influence of pirarubicin intravesical therapy on serum soluble intercellular adhesion molecule-1 (sICAM-1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in patients with superficial bladder cancer (SBC).Methods:132 patients with SBC undergoing transurethral resection of bladder tumor (TURBT) were divided into control group and observation group according to the treatments, with 66 cases in each group.The patients in control group received mitomycin intravesical therapy after TURBT and those in observation group received pirarubicin intravesical therapy.The recurrence rate within 2 years after surgery and complication during treatment were observed in two groups.The changes in serum sICAM-1, VEGF and MMP-9 were compared between two groups 6 months after surgery.Results:The recurrence rate within 2 years after surgery in observation group was significantly lower than in control group, while the recurrence rate during 6 to 12 months after surgery and ectopic recurrence rate in observation group were significantly lower than in control group (P＜0.05).The time of recurrence in observation group was significantly later than in control group (P ＜0.05).The serum sICAM-1, VEGF and MMP-9 levels were significantly reduced in two groups 6 months after surgery as compared with those before operation and those indexes in observation group were lower than in control group (P＜0.05).There was no significant difference in complications between two groups during intravesical therapy (P＞0.05).Conclusions:Intravesicaltherapy of pirarubicin can effectively reduce serum sICAM-1, VEGF and MMP-9 levels in patients with SBC, and inhibit the recurrence of bladder cancer, and has good application value.